

**REMARKS**


In response to the Restriction Requirement, applicants elect Group I, Claims 9-20, 32 and 33, drawn to a method for treating a tumor comprising providing a composition comprising an effective amount of the compound recited in claim 9 and applying the composition to the tumor. In response to the requirement to elect a species, applicants elect M<sub>4</sub>N, tetra-O-methyl nordihydroguaiaretic acid for the purposes of the initial search.

Claim 9 has been amended to delete the last clause relating to the effective amount being any amount greater than 0 μM, as this is unnecessary. Claim 9 has also been amended for clarity to delete "substituent" and to recite "substituted or unsubstituted amino acid residue", as supported throughout the specification, e.g. in paragraphs 19 and 61 of the published application (Pub. No. 20040127562). Claim 20 has been amended to recite the proper chemical name of G<sub>4</sub>N, as shown in Figure 1 of the application. Claim 33 has been amended to insert "the" for clarity. No new matter has been added.

Early and favorable action on the application is respectfully requested.

Respectfully submitted,

Date: August 21, 2006

  
Ann S. Hobbs, Ph.D.  
Registration No. 36,830  
VENABLE  
P.O. Box 34385  
Washington, D.C. 20043-9998  
Telephone: (202) 344-4000  
Telefax: (202) 344-8300  
[ashobbs@venable.com](mailto:ashobbs@venable.com)